It is reported that the number of BM does not impact the oncological prognosis in the EGFR/ALK mutated NSCLC patients; in addition, the number of BM independently affect the survival in driver gene wild-type BM patients.[16] The ALK inhibitors including alectinib, ceritinib, brigatinib, lorlatinib have been designed to cross the blood-brain barrier more efficiently than crizotinib and achieve higher concentration in the CSF.[17] A pooled analysis of 2 trials confirmed the safety and efficacy of second-line bevacizumab and pemetrexed in NSCLC patients with BM.[18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.